Patents Assigned to Taivex Therapeutics Corporation
  • Thiazole compounds as protein kinase inhibitors
    Patent number: 11299489
    Abstract: Thiazole compounds of Formula (I) shown below and pharmaceutical compositions containing one of such compounds: wherein R1 and R2 are defined in the specification. Also disclosed are methods of inhibiting a tyrosine kinase and treating cancer associated with a tyrosine kinase with one of the thiazole compounds.
    Type: Grant
    Filed: November 19, 2020
    Date of Patent: April 12, 2022
    Assignees: National Health Research Institutes, Taivex Therapeutics Corporation
    Inventors: Weir-Torn Jiaang, Yu-Sheng Chao
  • Modulators of HEC1 activity and methods therefor
    Patent number: 10588909
    Abstract: Compounds, compositions, and methods for modulation of Hec1/Nek2 interaction are provided. Such compounds disrupt Nek2/Hec1 binding and may be useful as chemotherapeutic agents for neoplastic diseases.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: March 17, 2020
    Assignees: Taivex Therapeutics Corporation, Development Center For Biotechnology
    Inventors: Jiann-Jyh Huang, Shih-Hsien Chuang, Ying-Shuan Eda Lee, Yu-Ling Huang, Johnson Lau
  • Biomarkers for cancers responsive to modulators of HEC1 activity
    Patent number: 9976183
    Abstract: Contemplated compositions and methods are drawn to biomarkers and methods related to treatment of neoplastic disease with Hec1 inhibitor. Gene status and/or expression levels of Hec1(HEC), Rb(RB1), and/or p53 (TP53) may be useful as biomarkers for sensitivity to treatment with a Hec1 inhibitor. In addition, Hec 1 inhibitors may show synergistic effects when used in conjunction with cytotoxic drugs.
    Type: Grant
    Filed: November 19, 2012
    Date of Patent: May 22, 2018
    Assignee: TAIVEX THERAPEUTICS CORPORATION
    Inventors: Yu-Ling Huang, Johnson Lau
  • Modulators of HEC1 activity and methods therefor
    Patent number: 9409902
    Abstract: Compounds, compositions, and methods for modulation of Hec1/Nek2 interaction are provided. Especially preferred compounds disrupt Nek2/Hec1 binding and are therefore useful as chemotherapeutic agent for neoplastic diseases.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: August 9, 2016
    Assignee: Taivex Therapeutics Corporation
    Inventors: Johnson Lau, Jiann-Jyh Huang
  • Modulators of Hec1 activity and methods therefor
    Patent number: 8999983
    Abstract: Compounds, compositions, and methods for modulation of Hec1/Nek2 interaction are provided. Such compounds disrupt Nek2/Hec1 binding and may be useful as chemotherapeutic agents for neoplastic diseases.
    Type: Grant
    Filed: November 29, 2012
    Date of Patent: April 7, 2015
    Assignees: Taivex Therapeutics Corporation, Development Center of Biotechnology
    Inventors: Jiann-Jyh Huang, Shih-Hsien Chuang, Ying-Shuan Eda Lee, Yu-Ling Huang, Johnson Lau
  • Methods and compounds for inhibiting Hec1 activity for the treatment of proliferative diseases
    Patent number: 8252520
    Abstract: The present invention provides methods and compounds for inhibiting HEC1 activity for the treatment of diseases involving cell hyperproliferation, e.g. cancer. The present invention also provides methods of identifying compounds for inhibiting HEC1 activity.
    Type: Grant
    Filed: October 14, 2003
    Date of Patent: August 28, 2012
    Assignee: Taivex Therapeutics Corporation
    Inventors: Wen-Hwa Lee, Phang-Lang Chen, Yumay Chen